Clinical Electrochemotherapy for advanced superficial melanoma

摘要: Cutaneous and subcutaneous metastases represent the target of electrochemotherapy (ECT) occur in 2–20% melanoma patients, depending on primary tumor histopathological features. ECT has been successfully tested patients frame several early clinical trials that confirmed its high activity advanced, refractory disease. In 2006, technique was standardized thanks to European Standard Operating Procedure Electrochemotherapy (ESOPE) multicenter trial entered into routine oncological practice, mainly a palliative setting. Recently, some experiences with treatment have shown promising control rate electroporated tumors, although majority continue undergo repetitive applications due disease progression. Researchers are actively investigating new ways expand improve technology, or combination itself immunomodulatory agents cancers possibly elicit systemic effective antitumor response.